Back to discover

Protein / target

TNF receptor-associated factor 6

Encoded byTRAF6Q9Y4K3Homo sapiensSwiss-Prot
Antibody-tractable
Druggability
GO CC high conf
1
Research papers

Protein at a glance

Biological role

Protein-macromolecule adaptor

Strongest disease association

Ovarian neoplasm

Via encoding gene TRAF6 · Genetic evidence · score 0.42

Research activity

Emerging research

1 papers · latest 2001

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as ECSIT, IKBKG, IRAK1, AKT1 and AKT2.

View complete UniProt function annotation

E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as ECSIT, IKBKG, IRAK1, AKT1 and AKT2 (PubMed:11057907, PubMed:18347055, PubMed:19465916, PubMed:19713527, PubMed:27746020, PubMed:31620128). Also mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation (PubMed:19675569). Leads to the activation of NF-kappa-B and JUN (PubMed:16378096, PubMed:17135271, PubMed:17703191, PubMed:39920527). Seems to also play a role in dendritic cells (DCs) maturation and/or activation (By similarity). Represses c-Myb-mediated transactivation, in B-lymphocytes (PubMed:18093978, PubMed:18758450). Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor (PubMed:12140561, PubMed:19825828, PubMed:8837778). Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation (By similarity). Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production (By similarity). Acts as a regulator of the JNK and NF-kappa-B signaling pathways by initiating assembly of heterotypic 'Lys-63'-/'Lys-48'-linked branched ubiquitin chains that are then recognized by TAB2: TRAF6 catalyzes initial 'Lys-63'-linked-polyubiquitin chains that are then branched via 'Lys-48'-linked polyubiquitin by HUWE1 (PubMed:27746020). 'Lys-63'-/'Lys-48'-linked branched ubiquitin chains protect 'Lys-63'-linkages from CYLD deubiquitination (PubMed:27746020). Participates also in the TCR signaling by ubiquitinating LAT (PubMed:23514740, PubMed:25907557)

Subcellular location

CytoplasmCytoplasm, cell cortexNucleusLipid droplet
Domains and Gene Ontology detail (73)

Domains & features

MATH

Gene Ontology

  • CCD40 receptor complex
  • Ccell cortex
  • Ccytoplasm
  • Ccytoplasmic side of plasma membrane
  • Ccytosol
  • Cendosome membrane
  • Cextrinsic component of cytoplasmic side of plasma membrane
  • Cglutamatergic synapse
  • Clipid droplet
  • Cnucleus
  • Cperinuclear region of cytoplasm
  • Cplasma membrane

522 aa · 60 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingGOTranscriptional regulationGO
View supporting evidence

Immune signalling

  • ·antiviral innate immune response
  • ·cellular response to cytokine stimulus
  • ·innate immune response
  • ·interleukin-1-mediated signaling pathway

Transcriptional regulation

  • ·negative regulation of DNA-templated transcription
  • ·negative regulation of transcription by RNA polymerase II
  • ·positive regulation of transcription by RNA polymerase II

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TRAF6

Gene-level evidence surfaced through the gene TRAF6 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Ovarian neoplasm
0.42Limited support

Genetic evidence dominant · Open Targets 0.26

Chronic Kidney Disease-Mineral and Bone Disorder
0.38Limited support

Genetic evidence dominant · Open Targets 0.23

Severe Acute Respiratory Syndrome
0.24Preliminary

Pathway evidence dominant · Open Targets 0.37 · no direct causal or clinical evidence

Neoplasms
0.14Preliminary

Literature evidence dominant · Open Targets 0.11 · no direct causal or clinical evidence

Carcinoma, Hepatocellular
0.13Preliminary

Literature evidence dominant · Open Targets 0.10 · no direct causal or clinical evidence

View evidence synthesis (5)
Ovarian neoplasmLimited support
0.42
agreement 0.280.56
Genetic99%Literature1%

Open Targets aggregate 0.26 · 2 independent evidence families

Chronic Kidney Disease-Mineral and Bone DisorderLimited support
0.38
agreement 0.260.50
Genetic100%

Open Targets aggregate 0.23 · 1 independent evidence family

Severe Acute Respiratory SyndromePreliminary
0.24
agreement 0.010.47
Pathway100%

Open Targets aggregate 0.37 · 1 independent evidence family · no direct causal or clinical evidence

NeoplasmsPreliminary
0.14
agreement 0.000.41
Literature100%

Open Targets aggregate 0.11 · 1 independent evidence family · no direct causal or clinical evidence

Carcinoma, HepatocellularPreliminary
0.13
agreement 0.000.40
Literature100%

Open Targets aggregate 0.10 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Severe Acute Respiratory Syndrome0.37
Ovarian neoplasm0.26
Chronic Kidney Disease-Mineral and Bone Disorder0.23
Neoplasms0.11
Carcinoma, Hepatocellular0.10

Tractability

AntibodiesEmerging

Feasibility evidence (go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
AB · GO CC high confPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2001

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.